Literature DB >> 8781150

The use of color-coded duplex scanning in the selection of patients with lower extremity arterial disease for percutaneous transluminal angioplasty: a prospective study.

B H Elsman1, D A Legemate, F W van der Heyden, H de Vos, W P Mali, B C Eikelboom.   

Abstract

PURPOSE: To exploit the potential benefits of percutaneous transluminal angioplasty (PTA) in patients with short obstructive lesions in the lower extremity, it is preferable to select patients suitable for PTA before proceeding to hospital admission and angiography. The aim of this prospective study was to evaluate the role of color-coded duplex scanning in the correct selection of patients for PTA and its influence on planning the approach to the lesion.
METHODS: On the basis of clinical history, physical examination, pressure indices, and ultrasound duplex scanning, 109 patients were scheduled for PTA.
RESULTS: The indication for PTA was correct in 103 patients (94%), while the procedure was performed successfully in 98 patients (90%). The approach to the lesion was planned successfully in the majority of patients.
CONCLUSION: This study shows that it is justifiable to plan PTA on the basis of information obtained by duplex scanning. Results of the duplex scan may guide the catheterization route.

Entities:  

Mesh:

Year:  1996        PMID: 8781150     DOI: 10.1007/bf02570181

Source DB:  PubMed          Journal:  Cardiovasc Intervent Radiol        ISSN: 0174-1551            Impact factor:   2.740


  19 in total

1.  Colour-coded duplex ultrasonography in the selection of patients for endovascular surgery.

Authors:  R Vashisht; M R Ellis; C Skidmore; S D Blair; R M Greenhalgh; M K O'Malley
Journal:  Br J Surg       Date:  1992-10       Impact factor: 6.939

2.  Magnetic resonance angiography of peripheral runoff vessels.

Authors:  J P Carpenter; R S Owen; R A Baum; C Cope; C F Barker; H D Berkowitz; M A Golden; L J Perloff
Journal:  J Vasc Surg       Date:  1992-12       Impact factor: 4.268

3.  Spectral analysis criteria in duplex scanning of aortoiliac and femoropopliteal arterial disease.

Authors:  D A Legemate; C Teeuwen; H Hoeneveld; R G Ackerstaff; B C Eikelboom
Journal:  Ultrasound Med Biol       Date:  1991       Impact factor: 2.998

4.  A duplex criterion for aorto-iliac stenosis.

Authors:  A A de Smet; P J Kitslaar
Journal:  Eur J Vasc Surg       Date:  1990-06

5.  Spiral CT angiography: an alternative to conventional angiography.

Authors:  D A Bluemke; T P Chambers
Journal:  Radiology       Date:  1995-05       Impact factor: 11.105

6.  Guidelines for peripheral percutaneous transluminal angioplasty of the abdominal aorta and lower extremity vessels. A statement for health professionals from a special writing group of the Councils on Cardiovascular Radiology, Arteriosclerosis, Cardio-Thoracic and Vascular Surgery, Clinical Cardiology, and Epidemiology and Prevention, the American Heart Association.

Authors:  M J Pentecost; M H Criqui; G Dorros; J Goldstone; K W Johnston; E C Martin; E J Ring; J B Spies
Journal:  Circulation       Date:  1994-01       Impact factor: 29.690

7.  Non-invasive aortoiliac assessment.

Authors:  I C Currie; A J Jones; C J Wakeley; W G Tennant; Y G Wilson; R N Baird; P M Lamont
Journal:  Eur J Vasc Endovasc Surg       Date:  1995-01       Impact factor: 7.069

8.  Improved patient selection for angioplasty utilizing color Doppler imaging.

Authors:  P Collier; G Wilcox; D Brooks; S Laffey; T Dalton
Journal:  Am J Surg       Date:  1990-08       Impact factor: 2.565

9.  Impact of ultrasonographic duplex scanning on therapeutic decision making in lower-limb arterial disease.

Authors:  B H Elsman; D A Legemate; F H van der Heijden; H J de Vos; W P Mali; B C Eikelboom
Journal:  Br J Surg       Date:  1995-05       Impact factor: 6.939

10.  Screening patients with claudication from femoropopliteal disease before angioplasty using Doppler colour flow imaging.

Authors:  M R Whyman; I Gillespie; C V Ruckley; P L Allan; F G Fowkes
Journal:  Br J Surg       Date:  1992-09       Impact factor: 6.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.